StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

Ovid Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Ovid Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$58.28M. For fiscal 2025 it was -$42.17M. The highest annual figure on record is $124.45M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$42.17M–
FY2024Dec 31, 2024-$61.27M–
FY2023Dec 31, 2023-$58.71M–
FY2022Dec 31, 2022-$55.04M-144.2%
FY2021Dec 31, 2021$124.45M–
FY2020Dec 31, 2020-$81.12M–
FY2019Dec 31, 2019-$61.15M–
FY2018Dec 31, 2018-$52.79M–
FY2017Dec 31, 2017-$64.93M–
FY2016Dec 31, 2016-$22.48M–
FY2015Dec 31, 2015-$13.18M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.68M–
Q1 FY2026Mar 31, 2026-$17.81M–
Q4 FY2025Dec 31, 2025-$12.28M–
Q3 FY2025Sep 30, 2025-$12.51M–
Q2 FY2025Jun 30, 2025-$4.97M–
Q1 FY2025Mar 31, 2025-$12.41M–
Q4 FY2024Dec 31, 2024-$10.56M–
Q3 FY2024Sep 30, 2024-$13.06M–
Q2 FY2024Jun 30, 2024-$20.37M–
Q1 FY2024Mar 31, 2024-$17.28M–
Q4 FY2023Dec 31, 2023-$18.05M–
Q3 FY2023Sep 30, 2023-$11.88M–
Q2 FY2023Jun 30, 2023-$14.04M–
Q1 FY2023Mar 31, 2023-$14.75M–
Q4 FY2022Dec 31, 2022-$11.99M–
Q3 FY2022Sep 30, 2022-$12.65M–
Q2 FY2022Jun 30, 2022-$14.21M–
Q1 FY2022Mar 31, 2022-$16.19M-109.2%
Q4 FY2021Dec 31, 2021-$26.30M–
Q3 FY2021Sep 30, 2021-$11.63M–
Q2 FY2021Jun 30, 2021-$14.26M–
Q1 FY2021Mar 31, 2021$176.63M–
Q4 FY2020Dec 31, 2020-$21.51M–
Q3 FY2020Sep 30, 2020-$16.32M–
Q2 FY2020Jun 30, 2020-$23.06M–
Q1 FY2020Mar 31, 2020-$20.23M–
Q4 FY2019Dec 31, 2019-$17.21M–
Q3 FY2019Sep 30, 2019-$16.71M–
Q2 FY2019Jun 30, 2019-$13.25M–
Q1 FY2019Mar 31, 2019-$13.98M–
Q4 FY2018Dec 31, 2018-$13.07M–
Q3 FY2018Sep 30, 2018-$13.14M–
Q2 FY2018Jun 30, 2018-$13.18M–
Q1 FY2018Mar 31, 2018-$13.40M–
Q4 FY2017Dec 31, 2017-$11.03M–
Q3 FY2017Sep 30, 2017-$9.39M–
Q2 FY2017Jun 30, 2017-$10.27M–
Q1 FY2017Mar 31, 2017-$34.24M–
Q4 FY2016Dec 31, 2016-$7.56M–
Q3 FY2016Sep 30, 2016-$5.81M–

More Ovid Therapeutics figures

See a number that looks wrong?